The Economic Implications of GLP-1 Therapies
The Economic Implications of GLP-1 Therapies supports researchers through a conference on treatment costs, insurance, and broader economic effects to examine the economic implications of growing GLP-1 use.
Funder: National Bureau of Economic Research
Due Dates: December 15, 2026, at 11:59 p.m. ET (Papers and extended abstracts) | March 4, 2027 (Conference)
Funding Amounts: Economy-class travel and hotel expenses for up to two authors per paper
Summary: An NIH-supported NBER conference invites research on the economic implications of GLP-1 therapies for health spending, insurance, and broader economic outcomes.
Key Information: Papers presented at NBER meetings may not make policy recommendations.
Description
The NBER Center for Aging and Health Research, with support from the National Institutes of Health, will convene a research conference in Cambridge, Massachusetts, on the economics of GLP-1 therapies. The meeting examines factors affecting demand and supply, implications for health care spending and insurance markets, and broader economic effects. It responds to growing use of these treatments for weight loss and chronic disease, high costs, differing insurance coverage policies, and the emergence of data suitable for economic research.
The organizers welcome completed papers and work in progress from economics and related disciplines. Topics include chronic disease prevalence and treatment costs, public insurance coverage and budgets, pricing and competition, demand, pharmaceutical research and development, and individual and economy-wide outcomes.
